This article will make a summary of the top ten best-selling drugs in the world and provide readers with a brief introduction to the current best-selling drugs.

　　1, adalimumab

AbbVie's adalimumab topped the list with US $18.4 billion in 2017, far higher than lenalidomide, which ranked second in sales of US $8.1 billion. It is predicted that the sales of the drug will exceed US $20 billion in 2018 and is expected to become the first drug to cross this threshold in pharmaceutical history. The specific information of the drug is shown in the following table:

　　2, lenalidomide

Ranked second is lenalidomide from Celgene biopharmaceutical company in the United States, with sales of $8.1 billion in 2017. Unlike adalimumab, the drug is a small molecule chemical drug. See the table below for specific information:

　　3, etinercept

The drug's sales in 2017 were $8 billion, ranking third. It is a biological macromolecule drug, similar to the No. 1 adalimumab treatment field. See the table below for specific information:

　　4, infliximab

The drug is also a biological macromolecular drug, with sales of $7.7 billion in 2017, ranking fourth. See the table below for specific information:

　　5Trastuzumab

Roche's trastuzumab, which ranks fifth with $7.1 billion in sales, is also a biomacromolecule drug. The drug information is as follows:

　　6, bevacizumab

The drug is also Roche's blockbuster drug, which is also a biomacromolecule drug. Sales followed trastuzumab to $6.8 billion. The drug information is as follows:

　　7, Rivaroxaban

As one of the few small molecule drugs in TOP10, Bayer's rivaroxaban won the seventh place with sales of 6.2 billion US dollars. The drug information is as follows:

　　8Rituximab

The drug is another blockbuster of Roche, with sales of up to 5.9 billion US dollars. It is also a biological macromolecule drug with monoclonal antibodies. The drug information is as follows:

　　９, Aficip

Bayer's biomacromolecule drug Aflibercept ranks ninth with sales of US $5.8 billion as an ophthalmic drug. The specific information is as follows:

　　10, nivolumab

As the first PD-1 target drug on the market in China, the drug has sales of US $5.7 billion and is used to treat advanced squamous non-small cell lung cancer. The specific drug information is as follows:

From the above, it can be seen that the total sales of the top 10 best-selling drugs are as high as $79.7 billion, of which biological macromolecular drugs account for the vast majority, while chemical small molecule drugs account for only two seats, indicating the strong development momentum of biological macromolecular drugs. On the other hand, it also shows the unique advantages of biological macromolecular drugs in the field of related disease treatment.